Literature DB >> 10389569

Caffeine overdose in a premature infant: clinical course and pharmacokinetics.

B J Anderson1, T R Gunn, N H Holford, R Johnson.   

Abstract

The elimination of caffeine was investigated in a 1860 g, 31 week gestation neonate, following the accidental administration of a 160 mg.kg-1 dose. The first serum concentration measured was 217.5 mg.l-1 at 36.5 h after dosing. Fitting of time-concentration data was performed using non-linear regression with MKMODEL. A first order elimination model was superior to a mixed order model. Parameter estimates were: clearance 0.01 l.h-1, volume of distribution 1.17 litres, elimination half-life 81 h. Toxic manifestations included hypertonia, sweating, tachycardia, cardiac failure, pulmonary oedema and metabolic disturbances (metabolic acidosis, hyperglycaemia and creatine kinase elevation). An unusual feature of this infant's illness course was gastric dilatation. These signs resolved by day 7 at a serum concentration of 60-70 mg.l-1. Caffeine clearance has traditionally been reported as either an absolute value or as directly proportional to body weight. The per kilogram model gives an erroneous impression that clearance is greatest in early childhood and then decreases with age until adult rates are reached in late adolescence. Age-related clearance values reported in the literature were reviewed using an allometric 3/4 power model. This size model demonstrates that clearance increases in infancy and reaches adult rates within the first three months of life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389569     DOI: 10.1177/0310057X9902700316

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  11 in total

1.  Release and permeation kinetics of caffeine from bioadhesive transdermal films.

Authors:  Sara Nicoli; Paolo Colombo; Patrizia Santi
Journal:  AAPS J       Date:  2005-09-02       Impact factor: 4.009

Review 2.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.

Authors:  James D Morse; Luis Ignacio Cortinez; Brian J Anderson
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

Review 4.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Caffeine therapy in preterm infants.

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 6.  Caffeine citrate: a review of its use in apnoea of prematurity.

Authors:  A M Comer; C M Perry; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

Review 7.  The clinical toxicology of caffeine: A review and case study.

Authors:  Cyril Willson
Journal:  Toxicol Rep       Date:  2018-11-03

Review 8.  Caffeine-Related Deaths: Manner of Deaths and Categories at Risk.

Authors:  Simone Cappelletti; Daria Piacentino; Vittorio Fineschi; Paola Frati; Luigi Cipolloni; Mariarosaria Aromatario
Journal:  Nutrients       Date:  2018-05-14       Impact factor: 5.717

9.  (Rad 8)Caffeine prophylaxis to improve intermittent hypoxaemia in infants born late preterm: a randomised controlled dosage trial (Latte Dosage Trial).

Authors:  Elizabeth Anne Oliphant; Christopher J D McKinlay; David G McNamara; Jane Marie Alsweiler
Journal:  BMJ Open       Date:  2020-10-20       Impact factor: 2.692

10.  Pharmacodynamic Effects of Standard versus High Caffeine Doses in the Developing Brain of Neonatal Rats Exposed to Intermittent Hypoxia.

Authors:  Kutilda Soontarapornchai; Charles L Cai; Taimur Ahmad; Jacob V Aranda; Ivan Hand; Kay D Beharry
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.